GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19016536 | Liver | NAFLD | cellular response to peptide | 71/1882 | 359/18723 | 1.82e-08 | 2.09e-06 | 71 |
GO:00434346 | Liver | NAFLD | response to peptide hormone | 76/1882 | 414/18723 | 1.51e-07 | 1.09e-05 | 76 |
GO:00328685 | Liver | NAFLD | response to insulin | 53/1882 | 264/18723 | 6.99e-07 | 3.95e-05 | 53 |
GO:00160555 | Liver | NAFLD | Wnt signaling pathway | 74/1882 | 444/18723 | 8.98e-06 | 2.96e-04 | 74 |
GO:0018205 | Liver | NAFLD | peptidyl-lysine modification | 65/1882 | 376/18723 | 9.42e-06 | 3.02e-04 | 65 |
GO:01987385 | Liver | NAFLD | cell-cell signaling by wnt | 74/1882 | 446/18723 | 1.05e-05 | 3.33e-04 | 74 |
GO:00301115 | Liver | NAFLD | regulation of Wnt signaling pathway | 57/1882 | 328/18723 | 2.79e-05 | 7.46e-04 | 57 |
GO:00463241 | Liver | NAFLD | regulation of glucose import | 16/1882 | 59/18723 | 1.68e-04 | 3.06e-03 | 16 |
GO:0043543 | Liver | NAFLD | protein acylation | 43/1882 | 243/18723 | 1.70e-04 | 3.07e-03 | 43 |
GO:00425936 | Liver | NAFLD | glucose homeostasis | 45/1882 | 258/18723 | 1.71e-04 | 3.08e-03 | 45 |
GO:00335006 | Liver | NAFLD | carbohydrate homeostasis | 45/1882 | 259/18723 | 1.87e-04 | 3.29e-03 | 45 |
GO:0006473 | Liver | NAFLD | protein acetylation | 37/1882 | 201/18723 | 2.10e-04 | 3.61e-03 | 37 |
GO:0046326 | Liver | NAFLD | positive regulation of glucose import | 12/1882 | 39/18723 | 3.02e-04 | 4.75e-03 | 12 |
GO:0018394 | Liver | NAFLD | peptidyl-lysine acetylation | 32/1882 | 169/18723 | 3.24e-04 | 5.00e-03 | 32 |
GO:00108281 | Liver | NAFLD | positive regulation of glucose transmembrane transport | 13/1882 | 46/18723 | 4.35e-04 | 6.42e-03 | 13 |
GO:00108271 | Liver | NAFLD | regulation of glucose transmembrane transport | 18/1882 | 77/18723 | 5.06e-04 | 7.15e-03 | 18 |
GO:00033001 | Liver | NAFLD | cardiac muscle hypertrophy | 20/1882 | 99/18723 | 1.80e-03 | 1.85e-02 | 20 |
GO:00463231 | Liver | NAFLD | glucose import | 16/1882 | 74/18723 | 2.43e-03 | 2.27e-02 | 16 |
GO:00613183 | Liver | NAFLD | renal filtration cell differentiation | 7/1882 | 20/18723 | 2.44e-03 | 2.27e-02 | 7 |
GO:00721123 | Liver | NAFLD | glomerular visceral epithelial cell differentiation | 7/1882 | 20/18723 | 2.44e-03 | 2.27e-02 | 7 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KLF15 | SNV | Missense_Mutation | | c.1106N>T | p.Ser369Leu | p.S369L | Q9UIH9 | protein_coding | deleterious(0.02) | probably_damaging(0.989) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
KLF15 | SNV | Missense_Mutation | | c.521N>T | p.Ser174Leu | p.S174L | Q9UIH9 | protein_coding | tolerated(0.14) | benign(0.081) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
KLF15 | SNV | Missense_Mutation | novel | c.790C>T | p.Pro264Ser | p.P264S | Q9UIH9 | protein_coding | deleterious(0.03) | probably_damaging(0.997) | TCGA-AO-A0J3-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD |
KLF15 | SNV | Missense_Mutation | rs775981060 | c.397N>A | p.Val133Ile | p.V133I | Q9UIH9 | protein_coding | tolerated(0.28) | benign(0.019) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
KLF15 | SNV | Missense_Mutation | rs867343522 | c.904N>A | p.Gly302Ser | p.G302S | Q9UIH9 | protein_coding | tolerated(0.26) | benign(0.051) | TCGA-AR-A2LL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
KLF15 | SNV | Missense_Mutation | | c.832N>C | p.Phe278Leu | p.F278L | Q9UIH9 | protein_coding | deleterious(0.02) | possibly_damaging(0.883) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KLF15 | SNV | Missense_Mutation | | c.1219N>T | p.Arg407Trp | p.R407W | Q9UIH9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E2-A15C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
KLF15 | SNV | Missense_Mutation | novel | c.56N>C | p.Val19Ala | p.V19A | Q9UIH9 | protein_coding | tolerated_low_confidence(0.27) | benign(0.011) | TCGA-E2-A56Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
KLF15 | SNV | Missense_Mutation | | c.809N>T | p.Ser270Phe | p.S270F | Q9UIH9 | protein_coding | deleterious(0.02) | possibly_damaging(0.804) | TCGA-EW-A1PD-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Chemotherapy | docetaxel | SD |
KLF15 | SNV | Missense_Mutation | | c.436G>A | p.Glu146Lys | p.E146K | Q9UIH9 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-EK-A3GM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |